Reprogramming the lung microenvironment by inhaled immunotherapy fosters immune destruction of tumor.

Abstract:

:Due to their constant exposure to inhaled antigens, lungs represent a particularly immunosuppressive environment that limits excessive immune responses; however, cancer cells can exploit this unique environment for their growth. We previously described the ability of aerosolized CpG-ODN combined with Poly(I:C) (TLR9 and TLR3 agonists, respectively) to promote antitumor immunity in a B16 melanoma lung metastasis model. Here, we explored the possibility of improving the therapeutic efficacy of TLR9/TLR3 agonist combinations by including in the inhalant either an antibody directed to both Ly6G and Ly6C markers to locally deplete myeloid-derived suppressive cells (MDSCs) or IFNα to directly activate the natural killer (NK) and macrophage innate immune cells in the lung. Addition of nebulized anti-MDSC antibody RB6-8C5 to aerosolized CpG-ODN/Poly(I:C) resulted in reduced mRNA levels of immunsuppressive molecules (IL10, Arg-1, and Nos2), increased activation of resident NK cells and improved treatment outcome, with a significant reduction in established B16 melanoma lung metastases compared to treatment with CpG-ODN/Poly(I:C) alone. Likewise, addition of aerosolized IFNα led to increased mRNA levels of proinflammatory cytokines (IL15 and IFNγ) in the lung and recruitment of highly activated NK cells, with no evident signs of toxicity and with a significantly improved antitumor effect as compared with aerosolized CpG-ODN/Poly(I:C). Combining both IFNα and RB6-8C5 with CpG-ODN/Poly(I:C) did not produce an additive effect compared to IFNα + CpG-ODN/Poly(I:C) or RB6-8C5 + CpG-ODN/Poly(I:C). Our results indicate that the inhalation therapy is a feasible and non-invasive strategy to deliver immunodulatory molecules, including antibodies and cytokines that reprogram the lung tumor microenvironment to foster immune destruction of tumors.

journal_name

Oncoimmunology

journal_title

Oncoimmunology

authors

Le Noci V,Sommariva M,Tortoreto M,Zaffaroni N,Campiglio M,Tagliabue E,Balsari A,Sfondrini L

doi

10.1080/2162402X.2016.1234571

subject

Has Abstract

pub_date

2016-09-20 00:00:00

pages

e1234571

issue

11

eissn

2162-4011

issn

2162-402X

pii

1234571

journal_volume

5

pub_type

杂志文章
  • In situ loading of skin dendritic cells with apoptotic bleb-derived antigens for the induction of tumor-directed immunity.

    abstract::The generation and loading of dendritic cells (DC) ex-vivo for tumor vaccination purposes is laborious and costly. Direct intradermal (i.d.) administration of tumor-associated antigens could be an attractive alternative approach, provided that efficient uptake and cross-presentation by appropriately activated skin DCs...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/21624011.2014.946360

    authors: Ruben JM,Bontkes HJ,Westers TM,Hooijberg E,Ossenkoppele GJ,van de Loosdrecht AA,de Gruijl TD

    更新日期:2014-07-03 00:00:00

  • Bcl-2: Live and let die.

    abstract::Recent findings from our laboratory provide the first indication that overexpression of Bcl-2 in Eµ-myc transgenic cells enhances tumor immunosurveillance by inducing NKG2D ligands. Initial evidence suggests that this model is relevant to human patients. Thus, antitumor therapies that target Bcl-2 harbor the risk of r...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.19536

    authors: Putz EM,Schuster C,Sexl V

    更新日期:2012-08-01 00:00:00

  • Potent immunosuppressive effects of the oncometabolite R-2-hydroxyglutarate.

    abstract::Somatic gain-of-function mutations in isocitrate dehydrogenase (NADP(+)) 1, cytosolic (IDH1) or isocitrate dehydrogenase (NADP(+)) 2, mitochondrial (IDH2) are bona fide oncogenic drivers of acute myeloid leukemia and glioma because the neomorphic enzymes catalyze the synthesis of R-2-hydroxylutarate (R-2-HG), an oncom...

    journal_title:Oncoimmunology

    pub_type: 社论

    doi:10.1080/2162402X.2018.1528815

    authors: Galluzzi L,Kroemer G

    更新日期:2018-10-16 00:00:00

  • Strategies for purging CD96+ stem cells in vitro and in vivo: New avenues for autologous stem cell transplantation in acute myeloid leukemia.

    abstract::The persistence of leukemic stem cells (LSCs) in acute myeloid leukemia (AML) patients receiving chemotherapy may be responsible for the high frequency of relapse. The selective elimination of CD96+ AML-LSCs by means of CD96-specific monoclonal antibodies may be a promising therapeutic approach and revitalize autologo...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.24500

    authors: Staudinger M,Humpe A,Gramatzki M

    更新日期:2013-06-01 00:00:00

  • Enhancing the clinical coverage and anticancer efficacy of immune checkpoint blockade through manipulation of the gut microbiota.

    abstract::Although anticancer therapy with immune checkpoint blockers has seen unprecedented success, it fails to control neoplasia in most patients and often causes immune-related adverse events (irAEs). Our recent research shows the immunostimulatory and antitumor effects of CTLA-4 blockade depend on distinct Bacteroides spec...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2015.1132137

    authors: Pitt JM,Vétizou M,Gomperts Boneca I,Lepage P,Chamaillard M,Zitvogel L

    更新日期:2016-02-18 00:00:00

  • Primary sterile necrotic cells fail to cross-prime CD8(+) T cells.

    abstract::Necrotic cells are known to activate the innate immune system and trigger inflammation by releasing damage associated molecular patterns (DAMPs). However, how necrotic cells influence the induction of antigen-specific CD8(+) T cell-mediated adaptive immune responses under sterile conditions, in the absence of pathogen...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.21098

    authors: Gamrekelashvili J,Ormandy LA,Heimesaat MM,Kirschning CJ,Manns MP,Korangy F,Greten TF

    更新日期:2012-10-01 00:00:00

  • Immunogenic cell death in a combined synergic gene- and immune-therapy against cancer.

    abstract::It was previously demonstrated that engineered mesenchymal stem cells (MSCs) which express a high level of a very efficient modified gene CYP2B6* (CYP2B6TM-RED) acting as a suicide gene (MSC-2B6*) in combination with cyclophosphamide (CPA) constitute a powerful cell/gene therapy approach for solid tumors. In murine mo...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2019.1667743

    authors: Nayagom B,Amara I,Habiballah M,Amrouche F,Beaune P,de Waziers I

    更新日期:2019-09-27 00:00:00

  • IL-32 induces indoleamine 2,3-dioxygenase+CD1c+ dendritic cells and indoleamine 2,3-dioxygenase+CD163+ macrophages: Relevance to mycosis fungoides progression.

    abstract::Mycosis fungoides (MF) progresses from patch to tumor stage by expansion of malignant T-cells that fail to be controlled by protective immune mechanisms. In this study, we focused on IL-32, a cytokine, highly expressed in MF lesions. Depending on the other cytokines (IL-4, GM-CSF) present during in vitro culture of he...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2016.1181237

    authors: Ohmatsu H,Humme D,Gonzalez J,Gulati N,Möbs M,Sterry W,Krueger JG

    更新日期:2016-05-05 00:00:00

  • Deubiquitinases A20 and CYLD modulate costimulatory signaling via CD137 (4-1BB).

    abstract::TRAF2 dependent K63-polyubiquitinations have been recently shown to connect CD137 (4-1BB) stimulation to NF-κB activation. In a search of deubiquitinase enzymes (DUBs) that could regulate such a signaling route, A20 and CYLD were found to coimmunoprecipitate with CD137 and TRAF2 complexes. Indeed, overexpression of A2...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2017.1368605

    authors: Azpilikueta A,Bolaños E,Lang V,Labiano S,Aznar MA,Etxeberria I,Teijeira A,Rodriguez-Ruiz ME,Perez-Gracia JL,Jure-Kunkel M,Zapata JM,Rodriguez MS,Melero I

    更新日期:2017-09-21 00:00:00

  • Immunomodulation of the tumor microenvironment by Toll-like receptor-3 (TLR3) ligands.

    abstract::In hepatocellular carcinoma (HCC) patients, the intratumoral expression of Toll-like receptor-3 (TLR3) correlates with prolonged survival. We demonstrated that TLR3 ligands can operate through three independent mechanisms: by directly killing TLR3-expressing cancer cells, by inducing T- and natural killer (NK)-cell in...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.23493

    authors: Chew V,Abastado JP

    更新日期:2013-04-01 00:00:00

  • Hist-Immune signature: a prognostic factor in colorectal cancer using immunohistochemical slide image analysis.

    abstract::Computerized image analysis for whole-slide images has been shown to improve efficiency, accuracy, and consistency in histopathology evaluations. We aimed to assess whether immunohistochemistry (IHC) image quantitative features can reflect the immune status and provide prognostic information for colorectal cancer pati...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2020.1841935

    authors: Zhao K,Li Z,Li Y,Yao S,Huang Y,Wang Y,Zhang F,Wu L,Chen X,Liang C,Liu Z

    更新日期:2020-10-30 00:00:00

  • A phase 1 trial extension to assess immunologic efficacy and safety of prime-boost vaccination with VXM01, an oral T cell vaccine against VEGFR2, in patients with advanced pancreatic cancer.

    abstract::VXM01 is a first-in-kind orally applied tumor vaccine based on live attenuated Salmonella typhi carrying an expression plasmid encoding VEGFR2, an antigen expressed on tumor vasculature and a stable and accessible target for anti-angiogenic intervention. A recent randomized, placebo-controlled, phase I dose-escalation...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2017.1303584

    authors: Schmitz-Winnenthal FH,Hohmann N,Schmidt T,Podola L,Friedrich T,Lubenau H,Springer M,Wieckowski S,Breiner KM,Mikus G,Büchler MW,Keller AV,Koc R,Springfeld C,Knebel P,Bucur M,Grenacher L,Haefeli WE,Beckhove P

    更新日期:2018-01-16 00:00:00

  • Evaluation of programmed cell death protein 1 (PD-1) expression as a prognostic biomarker in patients with clear cell renal cell carcinoma.

    abstract::Programmed cell death protein 1 (PD-1) immune checkpoint inhibitors have shown activity in patients with advanced renal cell carcinoma (RCC). However, the role of PD-1 expression in tumor-infiltrating lymphocytes (TILs) as a biomarker for poor outcome is not clear. In this study, we evaluated the prognostic value of T...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2017.1413519

    authors: Kim KS,Sekar RR,Patil D,Dimarco MA,Kissick HT,Bilen MA,Osunkoya AO,Master VA

    更新日期:2018-01-10 00:00:00

  • Trial watch: Oncolytic viruses for cancer therapy.

    abstract::Oncolytic virotherapy is emerging as a promising approach for the treatment of several neoplasms. The term "oncolytic viruses" is generally employed to indicate naturally occurring or genetically engineered attenuated viral particles that cause the demise of malignant cells while sparing their non-transformed counterp...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.24612

    authors: Vacchelli E,Eggermont A,Sautès-Fridman C,Galon J,Zitvogel L,Kroemer G,Galluzzi L

    更新日期:2013-06-01 00:00:00

  • Novel treatment strategy with autologous activated and expanded natural killer cells plus anti-myeloma drugs for multiple myeloma.

    abstract::This proof-of-concept single-arm open-label phase I clinical trial (NCT02481934) studied the safety and efficacy of multiple infusions of activated and expanded natural killer (NKAE) cells in combination with anti-myeloma drugs in multiple myeloma patients. It included five patients with relapsed or refractory MM who ...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2016.1250051

    authors: Leivas A,Perez-Martinez A,Blanchard MJ,Martín-Clavero E,Fernández L,Lahuerta JJ,Martinez-Lopez J

    更新日期:2016-11-22 00:00:00

  • TIE-2 expressing monocytes in human cancers.

    abstract::Tumor-associated macrophages (TAM) are well known as a key player in the tumor microenvironment, which support cancer progression. More recently, a lineage of monocytes characterized by the expression of the TIE-2/Tek angiopoietin receptor identified a subset of circulating and tumor-associated monocytes endowed with ...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2017.1303585

    authors: Turrini R,Pabois A,Xenarios I,Coukos G,Delaloye JF,Doucey MA

    更新日期:2017-03-16 00:00:00

  • Linking oncogenesis and immune system evasion in acquired resistance to EGFR-targeting antibodies: Lessons from a preclinical model.

    abstract::Searching for biomarkers that associated with the acquired resistance of malignant cells to epidermal growth factor receptor (EGFR)-targeting monoclonal antibodies is crucial to improve the clinical benefits of these therapeutic agents. We have recently demonstrated that molecular alterations in both oncogenic and imm...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.26904

    authors: Garrido G,Rabasa A,Sánchez B

    更新日期:2013-12-01 00:00:00

  • CD40L coding oncolytic adenovirus allows long-term survival of humanized mice receiving dendritic cell therapy.

    abstract::Dendritic cells (DCs) are crucial players in promoting immune responses. Logically, adoptive DC therapy is a promising approach in cancer immunotherapy. One of the major obstacles in cancer immunotherapy in general is the immunosuppressive tumor microenvironment, which hampers the maturation and activation of DCs. The...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2018.1490856

    authors: Zafar S,Sorsa S,Siurala M,Hemminki O,Havunen R,Cervera-Carrascon V,Santos JM,Wang H,Lieber A,De Gruijl T,Kanerva A,Hemminki A

    更新日期:2018-08-15 00:00:00

  • Immunosurveillance in esophageal carcinoma: The decisive impact of regulatory T cells.

    abstract::Neoadjuvant radiochemotherapy of esophageal carcinomas causes a variable degree of depletion of tumor-infiltrating FOXP3+ regulatory T cells (Tregs). The frequency of local Tregs in the operative specimens negatively correlates with the pathological response and overall patient survival. These results underscore the i...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2015.1064581

    authors: Vacchelli E,Semeraro M,Adam J,Dartigues P,Zitvogel L,Kroemer G

    更新日期:2015-07-01 00:00:00

  • Tumor infiltrating CD8+ T lymphocyte count is independent of tumor TLR9 status in treatment naïve triple negative breast cancer and renal cell carcinoma.

    abstract::Toll-like receptor 9 (TLR9) is a cellular DNA-receptor of the innate immune system that is widely expressed in cancers. We demonstrated that low tumor TLR9 expression predicts poor disease-specific survival in triple negative breast cancer (TNBC) and renal cell carcinoma (RCC). We hypothesized that this is because TLR...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2014.1002726

    authors: Mella M,Kauppila JH,Karihtala P,Lehenkari P,Jukkola-Vuorinen A,Soini Y,Auvinen P,Vaarala MH,Ronkainen H,Kauppila S,Haapasaari KM,Vuopala KS,Selander KS

    更新日期:2015-05-22 00:00:00

  • Co-stimulatory signaling determines tumor antigen sensitivity and persistence of CAR T cells targeting PSCA+ metastatic prostate cancer.

    abstract::Advancing chimeric antigen receptor (CAR)-engineered adoptive T cells for the treatment of solid cancers is a major focus in the field of immunotherapy, given impressive recent clinical responses in hematological malignancies. Prostate cancer may be amenable to T cell-based immunotherapy since several tumor antigens, ...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2017.1380764

    authors: Priceman SJ,Gerdts EA,Tilakawardane D,Kennewick KT,Murad JP,Park AK,Jeang B,Yamaguchi Y,Yang X,Urak R,Weng L,Chang WC,Wright S,Pal S,Reiter RE,Wu AM,Brown CE,Forman SJ

    更新日期:2017-10-16 00:00:00

  • CD44v3 protein-carrying tumor-derived exosomes in HNSCC patients' plasma as potential noninvasive biomarkers of disease activity.

    abstract::The molecular cargo of tumor-cell-derived exosomes (TEX) mimics that of parental tumor cells. Thus, TEX could potentially serve as noninvasive biomarkers of cancer progression. However, separation of TEX from non-TEX in patients' plasma requires tumor antigen-specific detection reagents. CD44v3 has been of interest as...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2020.1747732

    authors: Theodoraki MN,Matsumoto A,Beccard I,Hoffmann TK,Whiteside TL

    更新日期:2020-04-07 00:00:00

  • M1-like TAMs are required for the efficacy of PD-L1/PD-1 blockades in gastric cancer.

    abstract::The efficacy of PD-1/PD-L1 blockades is heterogeneous in different molecular subtypes of gastric cancer (GC). In this study, we analyzed relevant clinical trials to identify the molecular subtypes associated with the efficacy of PD-1/PD-L1 blockades, and public datasets, patient samples, and GC cell lines were used fo...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2020.1862520

    authors: Zhao R,Wan Q,Wang Y,Wu Y,Xiao S,Li Q,Shen X,Zhuang W,Zhou Y,Xia L,Song Y,Chen Y,Yang H,Wu X

    更新日期:2020-12-30 00:00:00

  • Tregs activated by bispecific antibodies: Killers or suppressors?

    abstract::In recent years, bispecific antibodies (bsAb) have emerged as promising tools for a target-specific redirection of T cells in order to eliminate malignant cells. However, CD3-engaging constructs might also activate T regulatory cells (Tregs) present in the tumor microenvironment. Whether this has detrimental or benefi...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/2162402X.2014.994441

    authors: Koristka S,Cartellieri M,Arndt C,Feldmann A,Seliger B,Ehninger G,Bachmann MP

    更新日期:2015-01-23 00:00:00

  • The ecto-ATPDase CD39 is involved in the acquisition of the immunoregulatory phenotype by M-CSF-macrophages and ovarian cancer tumor-associated macrophages: Regulatory role of IL-27.

    abstract::Tumor-associated macrophages (TAM) are immunosuppressive cells that can massively accumulate in the tumor microenvironment. In patients with ovarian cancer, their density is correlated with poor prognosis. Targeting mediators that control the generation or the differentiation of immunoregulatory macrophages represents...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2016.1178025

    authors: d'Almeida SM,Kauffenstein G,Roy C,Basset L,Papargyris L,Henrion D,Catros V,Ifrah N,Descamps P,Croue A,Jeannin P,Grégoire M,Delneste Y,Tabiasco J

    更新日期:2016-04-28 00:00:00

  • Resistance of cyclooxygenase-2 expressing pancreatic ductal adenocarcinoma cells against γδ T cell cytotoxicity.

    abstract::The prostaglandin (PG) synthetase cyclooxygenase 2 (Cox-2) promotes tumorigenesis, tumor progression, and metastasis in a variety of human cancer entities including pancreatic ductal adenocarcinoma (PDAC). In this study, we demonstrate that in PDAC cells such as Colo357 cells, enhanced Cox-2 expression and increased r...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/2162402X.2014.988460

    authors: Gonnermann D,Oberg HH,Kellner C,Peipp M,Sebens S,Kabelitz D,Wesch D

    更新日期:2015-01-07 00:00:00

  • Enhancing natural killer cell-mediated lysis of lymphoma cells by combining therapeutic antibodies with CD20-specific immunoligands engaging NKG2D or NKp30.

    abstract::Antibody-dependent cell-mediated cytotoxicity (ADCC) mediated through the IgG Fc receptor FcγRIIIa represents a major effector function of many therapeutic antibodies. In an attempt to further enhance natural killer (NK) cell-mediated ADCC, we combined therapeutic antibodies against CD20 and CD38 with recombinant immu...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2015.1058459

    authors: Kellner C,Günther A,Humpe A,Repp R,Klausz K,Derer S,Valerius T,Ritgen M,Brüggemann M,van de Winkel JG,Parren PW,Kneba M,Gramatzki M,Peipp M

    更新日期:2015-06-05 00:00:00

  • SOX2-specific adaptive immunity and response to immunotherapy in non-small cell lung cancer.

    abstract::Immunotherapeutic strategies including the blockade of programmed death 1 (PD-1) receptors hold promise for the treatment of various cancers including non-small cell lung carcinoma (NSCLC). Preclinical data suggest that pre-existing tumor immunity is important for disease regression upon checkpoint blockade-based ther...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.25205

    authors: Dhodapkar KM,Gettinger SN,Das R,Zebroski H,Dhodapkar MV

    更新日期:2013-07-01 00:00:00

  • Tumor-infiltrating follicular helper T cells: The new kids on the block.

    abstract::By analyzing CD4+ lymphocytes in human breast carcinomas, we have recently uncovered the presence of follicular helper T cells in lesions exhibiting an extensive immune infiltrate. The presence of these specialized CD4+ T cells, which localize to the germinal centers of peritumoral tertiary lymphoid structures found i...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.26066

    authors: Gu-Trantien C,Willard-Gallo K

    更新日期:2013-10-01 00:00:00

  • Sustained CD4+ T cell-driven lymphopenia without a compensatory IL-7/IL-15 response among high-grade glioma patients treated with radiation and temozolomide.

    abstract::Prolonged lymphopenia correlating with decreased survival commonly occurs among glioma patients undergoing radiation therapy (RT) and temozolomide (TMZ) treatment. To better understand the pathophysiology of this phenomenon, we prospectively monitored serum cytokine levels and lymphocyte subsets in 15 high-grade gliom...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.27357

    authors: Ellsworth S,Balmanoukian A,Kos F,Nirschl CJ,Nirschl TR,Grossman SA,Luznik L,Drake CG

    更新日期:2014-01-01 00:00:00